Introduction to the In-Vitro Diagnostic Regulation (IVDR)

This two-day seminar will clarify the requirements applicable to in-vitro diagnostic devices under the IVD Regulation (EU) 2017/746. It will highlight the major changes to responsibility and product data expectations and will review the impact to industry.

Brochure will be available shortly.

26-27 Nov 2018

& 21-22 May 2019 , 19-20 Nov 2019

GBP 1,499 1,299 *
EUR 2,099 1,819 *
USD 2,338 2,026 *
* When you book before 28 Sep

Book now

Course Overview

The new In-Vitro Diagnostic Device Regulation (EU) 2017/746 came into force in May 2017 with a transition period of 5 years. The IVD Regulation is significantly different from the IVD Directive, including changed classification rules and requirements for conformity assessment. It is intended to strengthen the current approval system for in-vitro diagnostics, making substantial changes to the existing IVD Directive (98/79/EC) legislation.

The IVD Regulation introduces a new risk-rule classification system based on the Global Harmonization Task Force (GHTF) rules for classification which, for the first time, takes patient impact into consideration. This change to the classification system will have an impact on all manufacturers of IVDs. The majority of IVDs are currently self-declare devices but under the new regulation about 80% of IVDs require some form of conformity assessment by a Notified Body.

Practical workshops over the two days will help consolidate the information provided.

Why you should attend

By attending this course, you will:

  • Gain a comprehensive overview of the new IVD regulation
  • Be aware of how the role of the Notified Body will change under the IVD regulation
  • Understand the requirements of the Technical Documentation for an IVD
  • Plan your labelling requirements and strategies
  • Know the key changes to ISO13485
  • Learn how IVDSs are classified
  • Understand the requirements for clinical evidence
  • Know the vigilance and Post Market Surveillance (PMS) requirements for IVDS

Who should attend

  • Regulatory affairs personnel
  • Persons responsible for regulatory compliance
  • Quality assurance professionals
  • Those responsible for OEM/Subcontractor control of IVDs
  • Economic operators, importers, distributors

Programme at a glance...

Day One

Introduction to IVDs

Historical overview of the current IVD Directive (98/79/EC)

Introduction to IVD regulation (EU) 2017/746

Notified Bodies (NB)

Key changes to IVD Regulation

Compiling the technical documentation for an IVD

Labelling requirements and strategies

Day one wrap up and introduction to day two

Clos of day one

Day Two

Welcome and recap on day one

ISO13485:2016

Risk-Based classification

Workshop – Product classification

Risk management

Workshop – Risk management

Clinical evidence and common specifications

Vigilance and Post Market Surveillance (PMS)

Case studies: Reporting/recalls

Key timelines and practical considerations

Discussion: Preparing a roadmap for transition

Wrap and close of forum

Presenters

Nancy Consterdine (26-27 Nov 2018)

Nancy Consterdine. This MDTI expert is a joint director in her own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices, focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016.

She has over 30 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex II list products. Also identifying regulatory strategies around global submissions (EU, FDA, Health Canada, TGA, Russia, Latin America and China). She has a special interest in labelling and UDI requirements.

Stuart Angell (26-27 Nov 2018)

Stuart Angell, This MDTI expert is a joint director in his own consultancy specialising in global regulatory affairs strategy and compliance for in vitro diagnostics and medical devices focusing on the transition to the new IVD/Medical Device Regulations, MDSAP and ISO13485:2016.

He has over 15 years in the IVD industry and in previous roles has been responsible for designing, reviewing and maintaining regulatory frameworks for self-declared and annex list II products including technical documentation for EU and global submissions (FDA, Health Canada, TGA, Russia, Latin America). He has an excellent understanding of risk management, Post Market Surveillance (PMS) and vigilance.

Book now

26-27 Nov 2018
26-27 Nov 2018 Cavendish Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
GBP 1,299.00
EUR 1,819.00
USD 2,026.00
Until 28 Sep
Enrol now
21-22 May 2019
21-22 May 2019 Rembrandt Hotel, London GBP 1,499.00
EUR 2,099.00
USD 2,338.00
+ VAT @ 20.00%
Enrol now
19-20 Nov 2019
19-20 Nov 2019 Venue not yet confirmed
+ VAT @ 20.00%
Enrol now

You may also be interested in

Previous customers include...

  • Alifax SPA
  • BD & Company
  • Beckman Coulter
  • Becton Dickinson
  • Becton Dickinson (Pty) Ltd
  • Becton Dickinson BV
  • Becton Dickinson East Africa Limited
  • Binding Site Group Ltd
  • Biotop Medical
  • Danaher
  • DGM Denmark A/S
  • Di Renzo SRL
  • Fujirebio-Europe NV
  • GlaxoSmithKline
  • INNOGENETICS
  • International Fund Services (Ireland) Ltd/IFS
  • Janssen Pharmaceutica NV
  • Medical Lab Science Council of Nigeria
  • Medical Laboratory Science Council of Nigeria
  • Medicines and Healthcare Products Regulatory Agency (MHRA)
  • Medicines and Medical Devices Agency of Serbia
  • NAMSA Medvance
  • Novartis Consumer Health SA
  • Omron Healthcare Europe BV
  • PA Consulting Group
  • Psephos Biomedica
  • Saudi Food and Drug Authority
  • Sekisui Diagnostics (UK) Ltd
  • Sestria Ltd
  • SPD Development Company Limited